14 9月 2020 by admin in UncategorizedComments NextCure Announces Appointment of John G. Houston, Ph.D., to its Board of Directors
09 9月 2020 by admin in UncategorizedComments Syros Announces Appointment of S. Gail Eckhardt, M.D., to its Board of Directors
24 8月 2020 by admin in UncategorizedComments Arcellx Announces EvansMDS Grant Awarded for Collaboration with Johns Hopkins and University of Colorado Researchers to Support Development of Arcellx ARC-sparX Platform Candidate ACLX-002
06 8月 2020 by admin in UncategorizedComments Syros Reports Second Quarter 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
30 7月 2020 by admin in UncategorizedComments Syros to Report Second Quarter 2020 Financial Results on Thursday, August 6, 2020
30 7月 2020 by admin in UncategorizedComments resTORbio Provides Corporate Update and Reports Second Quarter 2020 Financial Result
28 7月 2020 by admin in UncategorizedComments resTORbio Announces an Award from the National Institute on Aging to Fund a Pilot Study of RTB101 as COVID-19 Prophylaxis in Older Adults
22 6月 2020 by admin in UncategorizedComments TEMPEST THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED WITH THE COMBINATION OF TPST-1120 PLUS NIVOLUMAB IN A PHASE 1 STUDY IN PATIENTS WITH ADVANCED SOLID TUMORS
28 5月 2020 by admin in UncategorizedComments resTORbio Announces Initiation of Study to Evaluate if Antiviral Prophylaxis with RTB101 Reduces the Severity of COVID-19 in Nursing Home Residents
07 5月 2020 by admin in UncategorizedComments TEMPEST THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN TPST-1495 CLINICAL STUDY: DUAL EP2/4 ANTAGONIST TARGETING SOLID TUMORS
07 5月 2020 by admin in UncategorizedComments resTORbio Provides Corporate Update and Reports First Quarter 2020 Financial Results
07 5月 2020 by admin in UncategorizedComments Syros Reports First Quarter 2020 Financial Results and Highlights Recent Accomplishments and Anticipated Milestones
05 5月 2020 by admin in UncategorizedComments Crescendo Biologics and Cancer Research UK sign Clinical Development Partnership to develop CB213, a novel bispecific Humabody® therapeutic
29 4月 2020 by admin in UncategorizedComments resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology
13 4月 2020 by admin in UncategorizedComments NextCure Provides Update on Clinical Trial Activities Due to Impact of COVID-19 Pandemic
20 3月 2020 by admin in UncategorizedComments Design Therapeutics Launches with $45 Million to Develop a New Class of Disease-Modifying Therapies for Serious Degenerative Disorders
20 3月 2020 by admin in UncategorizedComments Design Therapeutics Launches with $45 Million to Develop a New Class of Disease-Modifying Therapies for Serious Degenerative Disorders
12 3月 2020 by admin in UncategorizedComments resTORbio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
12 3月 2020 by admin in UncategorizedComments NextCure Reports Fourth Quarter and Full Year 2019 Financial Results
12 3月 2020 by admin in UncategorizedComments Arcellx Announces FDA Orphan Drug Designation for CART-ddBCMA for the Treatment of Multiple Myeloma
28 2月 2020 by admin in UncategorizedComments Arcellx Announces First Patient Treated with T Cell Therapy Utilizing the Company’s Novel Binding Domain
30 1月 2020 by admin in UncategorizedComments TEMPEST THERAPEUTICS ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR TPST-1495 AND WELCOMES NEW INVESTORS
20 12月 2019 by admin in UncategorizedComments Syros Announces Appointment of Mark Alles to Its Board of Directors
18 12月 2019 by admin in UncategorizedComments GBT and Syros Partner to Discover, Develop and Commercialize Novel Therapies for Sickle Cell Disease and Beta Thalassemia
03 12月 2019 by admin in UncategorizedComments Centrexion Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Lead Pipeline Candidate CNTX-4975
15 11月 2019 by admin in UncategorizedComments resTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary Endpoint
14 11月 2019 by admin in UncategorizedComments NextCure Announces Pricing of Public Offering of Common Stock
12 11月 2019 by admin in UncategorizedComments Syros Reports Third Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
12 11月 2019 by admin in UncategorizedComments NextCure Announces Proposed Public Offering of Common Stock
09 11月 2019 by admin in UncategorizedComments NextCure Presents Updated Clinical Data from NC318 Phase 1/2 Clinical Trial at the 34th Annual Meeting of Society for Immunotherapy of Cancer (SITC) and Announces Initiation of Phase 2 Portion of the Trial
08 11月 2019 by admin in UncategorizedComments Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 American College of Rheumatology Annual Meeting and the 2019 American Academy of Physical Medicine and Rehabilitation Annual Assembly
05 11月 2019 by admin in UncategorizedComments Syros to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
05 11月 2019 by admin in UncategorizedComments resTORbio Reports Third Quarter 2019 Financial Results and Corporate Update
04 11月 2019 by admin in UncategorizedComments NextCure to Host and Webcast Event at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
